MedTrace Logo

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

NCT00414076 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-11-20

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is learn if taking Femara (letrozole) after a hysterectomy (surgical removal of the uterus) for uterine leiomyosarcoma will delay or prevent the cancer from coming back.

Conditions

  • Leiomyosarcoma
  • Uterine Neoplasm

Interventions

DRUG

Letrozole

2.5 mg Tablet By Mouth Daily for 12 Weeks.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Robert Coleman, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-19
Primary Completion
2017-07-13
Completion
2017-07-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00414076 on ClinicalTrials.gov